[WEBINAR] Biopharma Dealmaking 2026: Trends, Shifts, and What Comes Next

In 2025, biopharma deal activity rebounded sharply, driven by a looming patent cliff and renewed urgency among large pharma to secure de-risked growth. Heading into 2026, the playbook is evolving again, with acquirers increasingly looking beyond single assets toward platforms, differentiated modalities, and ecosystem positioning in high-velocity areas such as oncology, cell and gene therapy, and obesity and cardiometabolic adjacency. At the same time, China’s innovation engine is reshaping global sourcing strategies, accelerating China-to-West licensing and introducing new considerations around diligence, development strategy, and geopolitical risk.

In this webinar, Ipsos frames the latest dealmaking trends using recent transactions and market data, followed by a moderated discussion with active investors on what is changing in valuation, deal structures, and decision criteria, and what this means for pharma acquirers and innovator biotechs preparing for partnering conversations.

Speakers:

• Joel Sandler, PhD, Associate Partner, Ipsos Healthcare Advisory (Co-moderator)
• Linda Pullan, PhD, Founder, Pullan Consulting (Co-moderator)
• Michael King, Managing Director, Equity Research, Rodman & Renshaw (Panelist)
• Mark Simon, Advisor to CEO, Sun Pharma (Panelist)